CIA
TEVA icon

Capital Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Capital Investment Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-15,209
Closed -$505K – 476
2017
Q2 		$505K Sell
15,209
-1,845
-11% -$57.1K 0.04% 277
2017
Q1 		$547K Sell
17,054
-1,570
-8% -$53.6K 0.04% 262
2016
Q4 		$675K Sell
18,624
-960
-5% -$38.3K 0.06% 240
2016
Q3 		$901K Buy
19,584
+340
+2% +$17.7K 0.08% 210
2016
Q2 		$967K Buy
19,244
+1,801
+10% +$95.9K 0.09% 193
2016
Q1 		$933K Sell
17,443
-648
-4% -$38K 0.09% 184
2015
Q4 		$1.19M Sell
18,091
-98
-0.5% -$6.06K 0.12% 152
2015
Q3 		$1.03M Sell
18,189
-301
-2% -$19.5K 0.12% 156
2015
Q2 		$1.09M Sell
18,490
-1,096
-6% -$67.6K 0.12% 161
2015
Q1 		$1.22M Buy
19,586
+2
+0% +$116 0.13% 159
2014
Q4 		$1.13M Buy
19,584
+2
+0% +$111 0.12% 164
2014
Q3 		$1.05M Sell
19,582
-198
-1% -$10.5K 0.12% 160
2014
Q2 		$1.04M Sell
19,780
-398
-2% -$20.3K 0.12% 164
2014
Q1 		$1.07M Buy
20,178
+78
+0.4% +$3.6K 0.13% 155
2013
Q4 		$806K Buy
+20,100
New +$791K 0.11% 180

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital Investment Advisors's TEVA Position: Q3 2017 in Review

Capital Investment Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 15,209 shares — an estimated $505K sold.

Capital Investment Advisors first reported a position in TEVA in Q4 2013 and held it in 15 quarters. The position peaked at $1.22M in Q1 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Capital Investment Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Capital Investment Advisors sold 15,209 Teva Pharmaceuticals shares in Q3 2017, an estimated $505K.
  • Capital Investment Advisors first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 15 quarters.
  • Capital Investment Advisors's Teva Pharmaceuticals position peaked at $1.22M in Q1 2015.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Capital Investment Advisors's 13F filing for Q3 2017, filed 17 Oct 2017.